VBY-376, a small-molecule CTSB inhibitor for hepatic fibrosis/NASH, demonstrates robust preclinical efficacy, favorable preliminary human safety, and progress into Phase II trials [60]. This evidence concerns the gene CTSB and Hepatic fibrosis.